GPrX Data captures all the UK community prescribing data for hormone replacement therapies (HRT). Our online tool provides easy access to business intelligence for sales and marketing representatives.
Overall, prescribing for HRTs increased 8.5% in England and Wales in 2018 versus 2017 (by prescription items). Prescribing for adjunctive progestogen is the only class of HRT which saw a fall in prescribing in this period, falling 1.75% in terms of prescription items and 26.5% in terms of net ingredient cost. Sequential combined therapies saw the greatest increase in prescribing; rising 18.3% (items).
Unopposed oestrogen has the greatest market share of HRTs, representing 40.6% of prescription items in 2018.
Please use the drop down below to see RxIndexes for the adjunctive progestogen, continuous combined therapies, gonadomimetic drugs, sequential combined therapies and unopposed oestrogen markets.